Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 10/20 | 0.47 |
| ▸ | FBP1 | P09467 | 4/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999978 | 0.92 | ENPP1 (0.54) | ENPP1ALDH1A1EGFRPDGFRB | |
| SCHEMBL1013257 | 0.87 | ENPP1 (0.88) | ENPP1ALDH1A1EGFRFBP1ERBB2 | |
| SCHEMBL3427630 | 0.86 | ENPP1 (0.63) | ENPP1EGFRPDGFRB | |
| SCHEMBL8777 | 0.86 | ENPP1 (0.63) | ENPP1EGFRPDGFRB | |
| Hydrochloric Acid SCHEMBL9097 | 0.85 | ENPP1 (0.62) | ENPP1EGFRPDGFRB | |
| SCHEMBL24714036 | 0.85 | ENPP1 (0.48) | ENPP1EGFRFBP1ERBB2PDGFRB | |
| SCHEMBL4224921 | 0.84 | EGFR (0.48) | ENPP1EGFRERBB2PDGFRB | |
| SCHEMBL5231792 | 0.84 | ENPP1 (0.48) | ENPP1EGFRERBB2 | |
| SCHEMBL10290852 | 0.84 | EGFR (0.48) | ENPP1EGFRERBB2PDGFRB | |
| SCHEMBL3766549 | 0.83 | ENPP1 (0.52) | ENPP1EGFRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117693505-A | Heteroaryl derivative compounds and uses thereof | 沃若诺伊公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022225238-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 보로노이 주식회사 | 2022-10-27 | — | — | WO | disclosed |
| WO-2021231400-A1 | BIS-ARYL ETHERS CONTAINING N-ACYL AZETIDINE AS EGFR/HER2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| WO-2021231400-A1 | BIS-ARYL ETHERS CONTAINING N-ACYL AZETIDINE AS EGFR/HER2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20170081293-A1 | Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith | WAKE FOREST UNIVERSITY | 2017-03-23 | — | — | US | disclosed |
| EP-1369418-B1 | QUINAZOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| US-20040116422-A1 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1369418-A1 | QUINAZOLINE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081293-A1 | Functionalized Tyrosine Kinase Inhibitors Modified with Precious Metal Electrophiles and Methods Associated Therewith | ABL1, EGFR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ENPP1 4630/4885ALDH1A1 3502/4885EGFR 2/4885 |
| US-20070265260-A1 | Quinazoline derivatives | TYK2, ROR1, JAK1 | ENPP1 2877/4885ALDH1A1 3381/4885EGFR 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.